CME

This activity is supported by independent educational grants from AbbVie, Inc.; Pfizer, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Best of IBD Forum

Best of IBD Forum

This activity is supported by independent educational grants from AbbVie, Inc.; Pfizer, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Overview

Author(s)/Faculty: Stephen B. Hanauer, MD; William J. Sandborn, MD; Gary R. Lichtenstein, MD
Source: Healio - Gastroenterology Education Lab
Type: LectureArticles/Items: 6
Release Date: 11/27/2017Expiration Date: 11/26/2018
Credit Type: CMENumber of Credits: 1.5
Cost: FreeProvider: Vindico Medical Education
Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Substantial room for improvement in the care of patients with IBD is needed, as evidenced by a recent study of insurance claims that showed approximately 80% of 32,883 patients with IBD received suboptimal therapy. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies. To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD to avoid disease flares, prevent structural damage and disability, and restore quality of life. This program, Best of IBD Forum, will highlight several of the key presentations including disease severity and therapeutic targets as well as new therapies for the treatment of IBD.

CME Information

page 1 of 9